EnFuego Therapeutics
Pittsboro, US · Founded 2021 · Delaware corporation · 1 known investors
Early-stage oncology company developing a breakthrough siRNA platform to target undruggable cancer pathways.
Founders & leadership
MD
Michael DombeckExecutive
CV
Chad V. PecotNamed on SEC filing
Board
JM
Joe McMahonBoard director
SM
Sue MahonyBoard director
Investors · 1
Reported raises · per SEC filings
Form D private placements$1M disclosed across 1 round · 2021
▶$1MraisedOct 2025 · 12 investors · PharmaceuticalsRule 506(b)
▶$1MraisedOct 2025 · 12 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Joe McMahonDirector
- Chad V. PecotExecutive Officer, Director
- Michael DombeckExecutive Officer, Director
- Sue MahonyDirector
- Offering amount
- $2.5M
- Amount sold
- $1M
- First sale
- Jun 2021
- Incorporated
- Corporation, Delaware, 2021
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
In the news
Frequently asked questions
- What does EnFuego Therapeutics do?
- Early-stage oncology company developing a breakthrough siRNA platform to target undruggable cancer pathways.
- Who are EnFuego Therapeutics's investors?
- EnFuego Therapeutics's investors include Cape Fear BioCapital.
- How much funding has EnFuego Therapeutics raised?
- EnFuego Therapeutics has disclosed $1M raised across 1 round.
- Where is EnFuego Therapeutics headquartered?
- EnFuego Therapeutics is headquartered in Pittsboro, US.